The launch follows a Delhi High Court nod allowing sales of the cancer drug biosimilar ahead of patent expiry in May 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback